EUVIMEDEUVIMED entdecken
Crossref

SERS Fingerprinting of 100 kDa Serum Filtrates for Stage‐Specific Breast Cancer Diagnosis

Muqaddas Fatima, Aqsa Nawaz, Muhammad Irfan Majeed, Haq Nawaz, Nosheen Rashid, Najah Alwadie, Allah Ditta, Sumera Ahsan, Youmna Bano, Misbah Naeem, Aleena Ali, Eman Khalid und 3 weitere

ChemNanoMat · 2026-04 · 12 (4)

DOI: 10.1002/cnma.202500644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemNanoMat, online erschienen am 21.04.2026. Verfasst von Muqaddas Fatima und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer continues to be one of the most prevalent and life‐threatening malignancies amongwomen, emphasizing the demand for diagnostic methods that are rapid, sensitive, and noninvasive. This work explored the diagnostic utility of surface‐enhanced Raman spectroscopy (SERS) in conjunction with 100 kDa centrifugal filtration of serum samples, employing gold nanoparticles (AuNPs) as SERS substrate, for stage‐specific detection of breast cancer. Serum specimens collected from patients across four clinical stages, along with healthy controls, were analyzed, and their spectral profiles were subjected to chemometric evaluation using principal component analysis (PCA) and support vector machine (SVM) learning. The analysis revealed distinct biochemical signatures in proteins, lipids, nucleic acids, and carbohydrates that reflected disease progression. PCA enabled clear separation between spectra from healthy and cancer groups, while SVM classification delivered strong predictive performance, with area under the curve (AUC) values of 1.00, 0.93, and 0.89 for healthy, stage 3, and stage 4, respectively. Although early‐stage detection yielded moderate results, with AUC values of 0.55 and 0.71 for stages 1 and 2, the study demonstrates that AuNP‐based SERS integrated with advanced machine learning provides a promising, label‐free, and noninvasive platform for rapid breast cancer diagnosis and staging, with potential for clinical translation.

Zitieren

APA

Fatima, M., Nawaz, A., Majeed, M. I., Nawaz, H., Rashid, N., Alwadie, N., Ditta, A., Ahsan, S., Bano, Y., Naeem, M., Ali, A., Khalid, E., Zahid, L., Tariq, M. M., & Imran, M. (2026). SERS Fingerprinting of 100 kDa Serum Filtrates for Stage‐Specific Breast Cancer Diagnosis. ChemNanoMat, 12(4). https://doi.org/10.1002/cnma.202500644

Vancouver

Fatima M, Nawaz A, Majeed MI, Nawaz H, Rashid N, Alwadie N, et al. SERS Fingerprinting of 100 kDa Serum Filtrates for Stage‐Specific Breast Cancer Diagnosis. ChemNanoMat. 2026;12(4). doi:10.1002/cnma.202500644

BibTeX
@article{Fatima2026,
  author = {Fatima, Muqaddas and Nawaz, Aqsa and Majeed, Muhammad Irfan and Nawaz, Haq and Rashid, Nosheen and Alwadie, Najah and Ditta, Allah and Ahsan, Sumera and Bano, Youmna and Naeem, Misbah and Ali, Aleena and Khalid, Eman and Zahid, Laiba and Tariq, Muhammad Muaz and Imran, Muhammad},
  title = {SERS Fingerprinting of 100 kDa Serum Filtrates for Stage‐Specific Breast Cancer Diagnosis},
  journal = {ChemNanoMat},
  year = {2026},
  volume = {12},
  number = {4},
  doi = {10.1002/cnma.202500644}
}
Kostenlos starten →